LTZ Therapeutics
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1100 Island Dr Ste 103, Redwood City, Ca...Website
www.ltztherapeutics.comRevenue
$10.6 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
2
1
1
1
About LTZ Therapeutics
LTZs approach focuses on the fusion of reverse translational science, with a deep understanding of tumor microenvironment (TME) biology especially myeloid biology. Macrophages appear to be one of the most prevalent immune cell populations in TME of various hematologic and solid tumors. Therefore, effectively engaging and activating macrophages to kill cancer cells offers significant therapeutic potential for patients. LTZ is developing its own U-MCE Platform to primarily enhance the phagocytic function of monocytes and macrophages of different polarization states to foster anti-tumor immunity and offer potential therapeutic benefit for other non-oncology diseases.Explore more
LTZ Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is LTZ Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
LTZ Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on LTZ Therapeutics recently announced quarterly report
Product Launch: Get notified when LTZ Therapeutics launches new products
Check if LTZ Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if LTZ Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once LTZ Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at LTZ Therapeutics
Website visits: Recent activity has been detected on your website
Click to see if LTZ Therapeutics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at LTZ Therapeutics
Find more new buyers
Compare Similar Companies to LTZ Therapeutics
Compare insights from companies similar to LTZ Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
LTZ Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
LTZ Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about LTZ Therapeutics.
LTZ Therapeutics financials insights
Gather financial insights about LTZ Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Seed
$17M
2023
Other Financing Round
$27M
2024
Series A
$20M
2026
Other Financing Round
$38M
LTZ Therapeutics Tech Stack
A closer look at the technologies used by LTZ Therapeutics
Most Recent Scoops
Funding
Funding
Project
Research & Development, Product Management, Intellectual Property, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Funding
Funding
Funding
Funding
LTZ Therapeutics News & Media
LTZ Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of First-in-Class Myeloid Engager Immunotherapy, LTZ-301
REDWOOD CITY, Calif. & SHENZHEN, China--(BUSINESS WIRE)--FDA clears LTZ's IND application to initiate trial of its myeloid engager immunotherapy to treat relapsed or refractory non-Hodgkin lymphoma.LTZ Therapeutics Announces Over $20 Million Series A Financing for Development of its Myeloid Engager-Based Immunotherapy Pipeline
REDWOOD CITY, Calif. & SHENZHEN, China--(BUSINESS WIRE)--LTZ Therapeutics, an immunotherapy-focused biotech company, today announced the completion of the company’s Series A financing of over $20 million, to advance the development of its Myeloid Engager pipeline to treat cancer and autoimmune diseases. This round was led by new investor Lapam Capital and includes new investment participation from GL Ventures. In addition, the company has received continued investment from K2 Venture Partners aLTZ Announces over $10 Million Pre-A+ Financing to Advance Development of its Immunotherapy Pipeline to Treat Cancer and Autoimmune Diseases
REDWOOD CITY, Calif. & SHENZHEN, China--(BUSINESS WIRE)--LTZ Therapeutics – an immunotherapy-focused biotech company – today announced it has raised over $10 million in pre-A+ financing led by Qiming Venture Partners, with co-investor participation from Shunwei Capital, Lihehongxin Venture Capital Partnership and K2 Venture Partners. The closing of this round brings LTZ’s total funding to approximately $30 million since the company was founded in 2022. The proceeds from this round of funding wi
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding LTZ Therapeutics
Sign Up For FreeTo access detailed company insights
LTZs approach focuses on the fusion of reverse translational science, with a deep understanding of tumor microenvironment (TME) biology especially myeloid biology. Macrophages appear to be one of the most prevalent immune cell populations in TME of various hematologic and solid tumors. Therefore, effectively engaging and activating macrophages to k... Read More
